Advertisement

Tumor Biology

, Volume 35, Issue 7, pp 6913–6918 | Cite as

Cyclin D1 (CCND1) G870A polymorphisms and cervical cancer susceptibility: a Meta-analysis based on Ten case–control studies

  • Yongfu Wu
  • Hui Fu
  • Hanbin Zhang
  • Haohai Huang
  • Miao Chen
  • Li Zhang
  • Huiling Yang
  • Dongyun Qin
Research Article

Abstract

Many studies have evaluated the association between cyclin D1 (CCND1) G870A polymorphism and cervical cancer susceptibility. However, these studies showed inconsistent results. The aim of this study was to derive a more precise estimation of this association. We searched PubMed and Embase for related studies that had been published in English, and ten case–control studies with a total of 2,864 cases and 3,898 controls were finally identified to be eligible studies in the meta-analysis. The association was assessed by summarizing the odds ratios (ORs) with the corresponding 95 % confidence intervals (CIs). Overall, there was no significant association between cyclin D1 (CCND1) G870A polymorphism and cervical cancer risk (for the allele model A vs. G: OR = 1.02, 95 % CI 0.88–1.19, p = 0.76; for the co-dominant model AA vs. GG: OR = 1.03, 95 % CI 0.75–1.41, p = 0.85; for the dominant model AA + GA vs. GG: OR = 1.00, 95 % CI 0.78–1.28, p = 0.99; for the recessive comparison AA vs. GA + GG: OR = 1.06, 95 % CI 0.85–1.32, p = 0.62). In subgroup analysis by ethnicity, no significant difference was found in both Asians and Caucasians. In summary, the present meta-analysis provides evidence that genotypes for the cyclin D1 (CCND1) G870A polymorphism may be not associated with genetic susceptibility of cervical cancer.

Keywords

Cyclin D1 Polymorphism Cervical cancer Meta-analysis 

Notes

Acknowledgments

This work was supported by the National Natural Sciences Foundation of China (No. 81272334).

Conflicts of interest

None

References

  1. 1.
    Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011;378(9801):1461–84. doi: 10.1016/s0140-6736(11)61351-2.CrossRefPubMedGoogle Scholar
  2. 2.
    On the rise globally, cancer mortality declines in u.s. Cancer discovery. 2014;4(3):Of7. doi: 10.1158/2159-8290.cd-nb2014-006.
  3. 3.
    Amirian ES, Adler-Storthz K, Scheurer ME. Associations between human herpesvirus-6, human papillomavirus and cervical cancer. Cancer Lett. 2013;336(1):18–23. doi: 10.1016/j.canlet.2013.04.023.CrossRefPubMedGoogle Scholar
  4. 4.
    Whitlock EP, Vesco KK, Eder M, Lin JS, Senger CA, Burda BU. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155(10):687–97. doi: 10.7326/0003-4819-155-10-201111150-00376. W214-5.CrossRefPubMedGoogle Scholar
  5. 5.
    Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res. 1996;68:67–108.CrossRefPubMedGoogle Scholar
  6. 6.
    Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J. Alternate splicing produces a novel cyclin D1 transcript. Oncogene. 1995;11(5):1005–11.PubMedGoogle Scholar
  7. 7.
    Lu F, Gladden AB, Diehl JA. An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res. 2003;63(21):7056–61.PubMedGoogle Scholar
  8. 8.
    Wang N, Qian X, Wang S, Gao H, Wang L, Huo Y, et al. CCND1 rs9344 polymorphisms are associated with the genetic susceptibility to cervical cancer in Chinese population. Mol Carcinog. 2012;51(2):196–205. doi: 10.1002/mc.20801.CrossRefPubMedGoogle Scholar
  9. 9.
    Ni J, Wang M, Wang M, Fu S, Zhou D, Zhang Z, et al. CCND1 G870A polymorphism and cervical cancer risk: a case-control study and meta-analysis. J Cancer Res Clin Oncol. 2011;137(3):489–94. doi: 10.1007/s00432-010-0904-x.CrossRefPubMedGoogle Scholar
  10. 10.
    Catarino R, Pereira D, Breda E, Coelho A, Matos A, Lopes C, et al. Oncogenic virus-associated neoplasia: a role for cyclin D1 genotypes influencing the age of onset of disease? Biochem Biophys Res Commun. 2008;370(1):118–22. doi: 10.1016/j.bbrc.2008.03.039.CrossRefPubMedGoogle Scholar
  11. 11.
    Catarino R, Matos A, Pinto D, Pereira D, Craveiro R, Vasconcelos A, et al. Increased risk of cervical cancer associated with cyclin D1 gene A870G polymorphism. Cancer Genet Cytogenet. 2005;160(1):49–54. doi: 10.1016/j.cancergencyto.2004.11.017.CrossRefPubMedGoogle Scholar
  12. 12.
    Thakur N, Hussain S, Kohaar I, Tabassum R, Nasare V, Tiwari P, et al. Genetic variant of CCND1: association with HPV-mediated cervical cancer in Indian population. Biomark: Biochem Indic Expo Response Susceptibility Chem. 2009;14(4):219–25. doi: 10.1080/13547500902825274.CrossRefGoogle Scholar
  13. 13.
    Satinder K, Chander SR, Pushpinder K, Indu G, Veena J. Cyclin D1 (G870A) polymorphism and risk of cervix cancer: a case control study in north Indian population. Mol Cell Biochem. 2008;315(1–2):151–7. doi: 10.1007/s11010-008-9799-0.CrossRefPubMedGoogle Scholar
  14. 14.
    Castro FA, Haimila K, Sareneva I, Schmitt M, Lorenzo J, Kunkel N, et al. Association of HLA-DRB1, interleukin-6 and cyclin D1 polymorphisms with cervical cancer in the Swedish population–a candidate gene approach. Int J Cancer J Int Du Cancer. 2009;125(8):1851–8. doi: 10.1002/ijc.24529.CrossRefGoogle Scholar
  15. 15.
    Warchol T, Kruszyna L, Lianeri M, Roszak A, Jagodzinski PP. Distribution of CCND1 A870G polymorphism in patients with advanced uterine cervical carcinoma. Pathol Oncol Res: POR. 2011;17(1):133–7. doi: 10.1007/s12253-010-9293-3.CrossRefPubMedGoogle Scholar
  16. 16.
    Djansugurova LB, Perfilyeva AV, Zhunusova GS, Djantaeva KB, Iksan OA, Khussainova EM. The determination of genetic markers of age-related cancer pathologies in populations from Kazakhstan. Front Genet. 2013;4:70. doi: 10.3389/fgene.2013.00070.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Jeon YT, Kim JW, Song JH, Park NH, Song YS, Kang SB, et al. Cyclin D1 G870A polymorphism and squamous cell carcinoma of the uterine cervix in Korean women. Cancer Lett. 2005;223(2):259–63. doi: 10.1016/j.canlet.2004.12.024.CrossRefPubMedGoogle Scholar
  18. 18.
    Pharoah PD, Dunning AM, Ponder BA, Easton DF. Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer. 2004;4(11):850–60. doi: 10.1038/nrc1476.CrossRefPubMedGoogle Scholar
  19. 19.
    Klug SJ, Ressing M, Koenig J, Abba MC, Agorastos T, Brenna SM, et al. TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol. 2009;10(8):772–84. doi: 10.1016/s1470-2045(09)70187-1.CrossRefPubMedGoogle Scholar
  20. 20.
    Francisco G, Menezes PR, Eluf-Neto J, Chammas R. Arg72Pro TP53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case-control studies. Int J Cancer J Int Du Cancer. 2011;129(4):920–30. doi: 10.1002/ijc.25710.CrossRefGoogle Scholar
  21. 21.
    Castro FA, Ivansson EL, Schmitt M, Juko-Pecirep I, Kjellberg L, Hildesheim A, et al. Contribution of TMC6 and TMC8 (EVER1 and EVER2) variants to cervical cancer susceptibility. Int J Cancer J Int Du Cancer. 2012;130(2):349–55. doi: 10.1002/ijc.26016.CrossRefGoogle Scholar
  22. 22.
    Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70.CrossRefPubMedGoogle Scholar
  23. 23.
    Zhou C, An H, Hu M, Liu Q, Geng P, Xu J, et al. The cyclin D1 (CCND1) G870A polymorphism and lung cancer susceptibility: a meta-analysis. Tumour Biol: J Int Soc Oncodevelop Biol Med. 2013. doi: 10.1007/s13277-013-0968-8.Google Scholar
  24. 24.
    Zhang LQ, Wang J, Shang JQ, Bai JL, Liu FY, Guan X, et al. Cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a meta-analysis of 20 populations. Int J Color Dis. 2011;26(10):1249–55. doi: 10.1007/s00384-011-1220-x.CrossRefGoogle Scholar
  25. 25.
    Wang W, Zhao Y, Yang J, Lin B, Gu H, Cao X, et al. Cyclin D1 polymorphism and oral cancer: a meta-analysis. Mol Biol Rep. 2013;40(1):87–95. doi: 10.1007/s11033-012-2025-x.CrossRefPubMedGoogle Scholar
  26. 26.
    Tang C, Wang Z, Yu J, Wu Y, Zhu Z, Chen N. CCND1 G870A polymorphism and risk for head and neck cancer: a meta-analysis. Med Oncol (Northwood, London, England). 2011;28(4):1319–24. doi: 10.1007/s12032-010-9547-7.CrossRefGoogle Scholar
  27. 27.
    Sergentanis TN, Economopoulos KP. Cyclin D1 G870A polymorphism and breast cancer risk: a meta-analysis comprising 9,911 cases and 11,171 controls. Mol Biol Rep. 2011;38(8):4955–63. doi: 10.1007/s11033-010-0639-4.CrossRefPubMedGoogle Scholar
  28. 28.
    Li M, Dai W, Zhou H. Cyclin D1 G870A polymorphism and risk of nasopharyngeal carcinoma: a meta-analysis. Sci World J. 2013;2013:689048. doi: 10.1155/2013/689048.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Yongfu Wu
    • 1
  • Hui Fu
    • 1
  • Hanbin Zhang
    • 1
  • Haohai Huang
    • 1
  • Miao Chen
    • 1
  • Li Zhang
    • 1
  • Huiling Yang
    • 1
    • 2
    • 3
  • Dongyun Qin
    • 1
    • 3
  1. 1.Department of PharmacologyGuangdong Medical CollegeZhanjiangChina
  2. 2.Sino-American Cancer Research InstituteGuangdong Medical CollegeDongguanChina
  3. 3.ZhanjiangChina

Personalised recommendations